Accepting the Status Quo: Subject Matter Eligibility Nearly a Decade after Mayo
Wednesday, November 10, 3:00 pm EDT
This panel will discuss the reality that almost a decade after the Supreme Court’s decision in Mayo v. Prometheus, the current subject matter eligibility standard has become the status quo with little prospect for change. Panelists will discuss how innovators can best protect their technology under these circumstances, how subject matter jurisprudence has impacted the patent process, and whether incremental changes could improve the situation.
- Kevin Noonan, Partner, McDonnell Boehnen Hulbert & Berghof LLP (Moderator)
- Donald Zuhn Jr., Partner, McDonnell Boehnen Hulbert & Berghof LLP (Moderator)
- Derek Maetzold, President and CEO, Castle Biosciences, Inc.
- Cara Coburn, Associate General Counsel, Patent Law, Genentech
- June Cohan, Senior Legal Advisor, U.S. Patent & Trademark Office
112 Enablement: What to Watch Out For
Wednesday, September 29 at 1:00 PM EDT
Join us for an expert discussion on Section 112, focusing on the enablement of functional language. We'll review how this is playing out in district court litigation and in the PTAB and also discuss potential prosecution strategies. The discussion will focus on recent enablement-related cases, including Amgen v. Sanofi and the cases that led to that landmark decision.
- Michael Bunis, Practice Group Leader - IP Litigation, Choate Hall & Stewart, LLP (Moderator)
- Wendy Plotkin, In-House IP Counsel, Biogen
- Stephanie Schonewald, Principal, Choate Hall & Stewart, LLP
- Amy Bray, Director, IP & Associate General Counsel, Adimab, LLC
Sponsored By Choate Hall & Stewart LLP
Trade Secrets: An Ounce of Prevention is Worth a Pound of Cure
Wednesday, July 28 at 1:00 PM EDT
A critical part of strategic planning for biotech companies is managing trade secrets. A panel of experts will provide information on preventative measures to protect trade secrets and to minimize allegations of trade secret misappropriation, including: identifying and managing trade secrets; employee agreements, policies, training and separation procedures; disclosure of trade secrets to others; and managing third-party trade secrets.
- Christopher P. Borello, Partner, Venable LLP (Moderator)
- Dr. Tashica Amirgholizadeh, Associate General Counsel, Intellectual Property, Gilead Sciences, Inc.
- Danielle A. Lawrence, Associate, Venable LLP
- Brendan O’Malley, VP, Head of Legal & IP and Corporate Secretary, Abeona Therapeutics
Biotech Intellectual Property Law in Focus is a new webinar series offering timely, relevant insights into the latest issues in the biotech intellectual property sector. The series will focus on what's new and important in the biotech IP landscape today.
Subscribe for updates to be the first to know when new webinar episodes are announced!
Exploring the Implications of the Election for Biotechnology and the Patent System
December 3, 2020 | 1:00 PM - 2:30 PM ET
What does the election mean for the patent system, and IP policy affecting biotechnology? Which issues are likely to be important to the IP field in the coming Congress, and which initiatives and policies may be on the agenda for the administration? This webinar will discuss expectations for the composition of relevant committees in the next Congress and the direction of legislative IP work in the coming year. Also, we will explore prospects in the executive branch affecting the direction of domestic IP policy and trade policy.
- David Lachmann, Senior Director of Federal Government Relations, BIO (Moderator)
- Dana Robert Colarulli, Partner, American Continental Group
- Chris Israel, Partner, American Continental Group
- Brian Pomper, Partner, Akin Gump Strauss Hauer & Feld LLP
Gain more exposure for your company among the Biotech Intellectual Property community! Contact the BIO Sales & Sponsorship team to learn more about sponsoring an upcoming webinar episode.